Business Description
INIFY Laboratories AB
ISIN : SE0017486103
Description
INIFY Laboratories AB provides cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized, and AI-supported workflow to optimize quality and response times, initially within the prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer's organization.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.86 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 15.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.28 | |||||
| 9-Day RSI | 63.24 | |||||
| 14-Day RSI | 55.63 | |||||
| 6-1 Month Momentum % | -37.06 | |||||
| 12-1 Month Momentum % | -66.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.25 | |||||
| Quick Ratio | 5.12 | |||||
| Cash Ratio | 4.43 | |||||
| Days Inventory | 142.01 | |||||
| Days Sales Outstanding | 190.94 | |||||
| Days Payable | 740.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.45 | |||||
| Operating Margin % | -570.27 | |||||
| Net Margin % | -550.84 | |||||
| ROE % | -72.16 | |||||
| ROA % | -64.66 | |||||
| ROIC % | -229.27 | |||||
| ROC (Joel Greenblatt) % | -563.94 | |||||
| ROCE % | -71.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 24.41 | |||||
| PB Ratio | 4.75 | |||||
| Price-to-Tangible-Book | 5.25 | |||||
| EV-to-EBIT | -3.76 | |||||
| EV-to-EBITDA | -4.13 | |||||
| EV-to-Revenue | 20.68 | |||||
| Price-to-Net-Current-Asset-Value | 6.84 | |||||
| Price-to-Net-Cash | 8.39 | |||||
| Earnings Yield (Greenblatt) % | -26.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
INIFY Laboratories AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 9.643 | ||
| EPS (TTM) (kr) | -1.168 | ||
| Beta | 0 | ||
| Volatility % | 46.99 | ||
| 14-Day RSI | 55.63 | ||
| 14-Day ATR (kr) | 0.391315 | ||
| 20-Day SMA (kr) | 4.6395 | ||
| 12-1 Month Momentum % | -66.42 | ||
| 52-Week Range (kr) | 4 - 13.6 | ||
| Shares Outstanding (Mil) | 45.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
INIFY Laboratories AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
INIFY Laboratories AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
INIFY Laboratories AB Frequently Asked Questions
What is INIFY Laboratories AB(OSL:INIFY)'s stock price today?
The current price of OSL:INIFY is kr5.20. The 52 week high of OSL:INIFY is kr13.60 and 52 week low is kr4.00.
When is next earnings date of INIFY Laboratories AB(OSL:INIFY)?
The next earnings date of INIFY Laboratories AB(OSL:INIFY) is 2025-02-26.
Does INIFY Laboratories AB(OSL:INIFY) pay dividends? If so, how much?
INIFY Laboratories AB(OSL:INIFY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers